Cargando…

One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity

PURPOSE: To evaluate the one-year efficacy of intravitreal aflibercept injection in polypoidal choroidal vasculopathy (PCV) with best-corrected visual acuity (BCVA) of 20 / 40 or better. METHODS: This was a multicenter retrospective study. The medical records of patients diagnosed with treatment-naï...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Ji Min, Pak, Kang Yeun, Lee, Jae Jung, Sagong, Min, Kim, Hyun Woong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Ophthalmological Society 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904418/
https://www.ncbi.nlm.nih.gov/pubmed/33307629
http://dx.doi.org/10.3341/kjo.2020.0096
_version_ 1783654924400197632
author Kwon, Ji Min
Pak, Kang Yeun
Lee, Jae Jung
Sagong, Min
Kim, Hyun Woong
author_facet Kwon, Ji Min
Pak, Kang Yeun
Lee, Jae Jung
Sagong, Min
Kim, Hyun Woong
author_sort Kwon, Ji Min
collection PubMed
description PURPOSE: To evaluate the one-year efficacy of intravitreal aflibercept injection in polypoidal choroidal vasculopathy (PCV) with best-corrected visual acuity (BCVA) of 20 / 40 or better. METHODS: This was a multicenter retrospective study. The medical records of patients diagnosed with treatment-naïve PCV were retrospectively reviewed. Patients with an initial BCVA of 20 / 40 or better and who had undergone intravitreal aflibercept injection were included. Patients were treated with three consecutive monthly injections, followed by pro re nata regimen according to the clinician’s discretion at variable interval visits. The proportions of eyes for which BCVA was maintained (≤ 0.2 logarithm of the minimum angle of resolution change) or improved at 12 months were evaluated. The changes of BCVA, central subfield macular thickness (CSMT), pigment epithelial detachment, and subretinal fluid also were assessed. RESULTS: A total of 86 eyes were included. The mean number of injections for 12 months of treatment was 5.4 ± 1.7. BCVA was maintained or improved in 94.2% (81 / 86) of cases. Mean BCVA (logarithm of the minimum angle of resolution) had changed from the baseline (0.23 ± 0.09) at 3 months (0.21 ± 0.14), 6 months (0.24 ± 0.22), and 12 months (0.20 ± 0.18), but with no statistical significance. CSMT had improved significantly from the baseline (336.1 ± 97.3 μm) at 3 months (223.6 ± 47.22 μm), 6 months (239.6 ± 64.2 μm), and 12 months (223.8 ± 47.9 μm). Pigment epithelial detachment was observed in 93% of cases at the baseline, 72.1% at 3 months, and 69.8% at 12 months, showing a significant decrease at all observation points. Subretinal fluid was observed in 91.9% of cases at the baseline, 20.9% at 3 months, and 29.1% at 12 months, showing a significant decrease at all observation points. CONCLUSIONS: In cases of PCV with good visual acuity, intravitreal aflibercept injections decreased CSMT and were effective in maintaining visual acuity.
format Online
Article
Text
id pubmed-7904418
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Korean Ophthalmological Society
record_format MEDLINE/PubMed
spelling pubmed-79044182021-03-03 One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity Kwon, Ji Min Pak, Kang Yeun Lee, Jae Jung Sagong, Min Kim, Hyun Woong Korean J Ophthalmol Original Article PURPOSE: To evaluate the one-year efficacy of intravitreal aflibercept injection in polypoidal choroidal vasculopathy (PCV) with best-corrected visual acuity (BCVA) of 20 / 40 or better. METHODS: This was a multicenter retrospective study. The medical records of patients diagnosed with treatment-naïve PCV were retrospectively reviewed. Patients with an initial BCVA of 20 / 40 or better and who had undergone intravitreal aflibercept injection were included. Patients were treated with three consecutive monthly injections, followed by pro re nata regimen according to the clinician’s discretion at variable interval visits. The proportions of eyes for which BCVA was maintained (≤ 0.2 logarithm of the minimum angle of resolution change) or improved at 12 months were evaluated. The changes of BCVA, central subfield macular thickness (CSMT), pigment epithelial detachment, and subretinal fluid also were assessed. RESULTS: A total of 86 eyes were included. The mean number of injections for 12 months of treatment was 5.4 ± 1.7. BCVA was maintained or improved in 94.2% (81 / 86) of cases. Mean BCVA (logarithm of the minimum angle of resolution) had changed from the baseline (0.23 ± 0.09) at 3 months (0.21 ± 0.14), 6 months (0.24 ± 0.22), and 12 months (0.20 ± 0.18), but with no statistical significance. CSMT had improved significantly from the baseline (336.1 ± 97.3 μm) at 3 months (223.6 ± 47.22 μm), 6 months (239.6 ± 64.2 μm), and 12 months (223.8 ± 47.9 μm). Pigment epithelial detachment was observed in 93% of cases at the baseline, 72.1% at 3 months, and 69.8% at 12 months, showing a significant decrease at all observation points. Subretinal fluid was observed in 91.9% of cases at the baseline, 20.9% at 3 months, and 29.1% at 12 months, showing a significant decrease at all observation points. CONCLUSIONS: In cases of PCV with good visual acuity, intravitreal aflibercept injections decreased CSMT and were effective in maintaining visual acuity. Korean Ophthalmological Society 2021-02 2021-02-05 /pmc/articles/PMC7904418/ /pubmed/33307629 http://dx.doi.org/10.3341/kjo.2020.0096 Text en © 2021 The Korean Ophthalmological Society https://creativecommons.org/licenses/by-nc/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kwon, Ji Min
Pak, Kang Yeun
Lee, Jae Jung
Sagong, Min
Kim, Hyun Woong
One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity
title One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity
title_full One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity
title_fullStr One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity
title_full_unstemmed One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity
title_short One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity
title_sort one-year results of aflibercept treatment for polypoidal choroidal vasculopathy with good visual acuity
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904418/
https://www.ncbi.nlm.nih.gov/pubmed/33307629
http://dx.doi.org/10.3341/kjo.2020.0096
work_keys_str_mv AT kwonjimin oneyearresultsofaflibercepttreatmentforpolypoidalchoroidalvasculopathywithgoodvisualacuity
AT pakkangyeun oneyearresultsofaflibercepttreatmentforpolypoidalchoroidalvasculopathywithgoodvisualacuity
AT leejaejung oneyearresultsofaflibercepttreatmentforpolypoidalchoroidalvasculopathywithgoodvisualacuity
AT sagongmin oneyearresultsofaflibercepttreatmentforpolypoidalchoroidalvasculopathywithgoodvisualacuity
AT kimhyunwoong oneyearresultsofaflibercepttreatmentforpolypoidalchoroidalvasculopathywithgoodvisualacuity